Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRO-BID vs ISORDIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Prophylaxis of angina pectoris,Treatment of acute angina attacks,Off-label: acute myocardial infarction (limited use), heart failure with pulmonary edema (if not hypotensive)
Angina pectoris (prophylaxis and acute treatment),Heart failure (off-label: adjunctive treatment in acute myocardial infarction)
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Rapidly metabolized via hepatic glutathione-organic nitrate reductase to dinitrates and mononitrates; also metabolized in erythrocytes and vascular tissue.
Primarily hepatic via glutathione-organic nitrate reductase; also undergoes denitration to active metabolites (isosorbide-2-mononitrate and isosorbide-5-mononitrate).
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Approximately 60% bound to plasma proteins (mainly albumin).
~28% bound to albumin.
Vd approximately 3.3 L/kg, indicating extensive distribution into tissues beyond plasma volume.
2–4 L/kg, indicating extensive tissue distribution.
Sublingual: ~40% (high first-pass hepatic metabolism); Transdermal: ~72% (bypasses first-pass); Oral: <10% due to extensive hepatic metabolism.
Sublingual: ~40–60% (first-pass bypassed); oral: <30% due to extensive first-pass hepatic metabolism.
No specific adjustment required; nitroglycerin is minimally renally excreted.
No specific GFR-based dose adjustments are recommended; however, caution is advised in severe renal impairment due to potential accumulation of metabolites.
Child-Pugh A: no adjustment. Child-Pugh B: consider dose reduction (25-50% of normal dose). Child-Pugh C: avoid or use with extreme caution; reduce dose by 50% or more.
In Child-Pugh class A: no adjustment. Child-Pugh class B and C: reduce dose by 50% and monitor for hypotension.
Not routinely recommended; limited data. Intravenous: start at 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min every 3-5 min to effect; max 5 mcg/kg/min.
Isosorbide dinitrate: not recommended for use in children due to lack of safety and efficacy data; no established pediatric dosing guidelines.
Start at lower end of dosing range due to increased sensitivity and risk of hypotension. Sublingual: 0.3 mg initial. Transdermal: 0.2 mg/hour initially.
Elderly patients may have increased sensitivity to hypotension. Initiate with lowest doses (e.g., 5 mg orally twice daily) and titrate slowly. Monitor blood pressure and orthostatic changes.
No FDA boxed warning specifically for NITRO-BID. However, nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension.
Do not use in patients with erectile dysfunction medications (PDE-5 inhibitors) due to risk of severe hypotension.
May cause severe hypotension, especially with volume depletion; avoid in patients with hypertrophic cardiomyopathy; use caution in hepatic/renal impairment; tolerance develops with chronic use; may aggravate angina when discontinuing abruptly.
Hypotension (especially with volume depletion or alcohol),Tolerance with prolonged use (intermittent dosing recommended),Exacerbation of angina upon abrupt withdrawal,Use cautiously in hypertrophic cardiomyopathy
Hypersensitivity to nitrates; concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil); severe anemia; increased intracranial pressure; circulatory failure or shock; right ventricular infarction; constrictive pericarditis; cardiac tamponade.
Hypersensitivity to nitrates,Concurrent use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil),Severe anemia,Increased intracranial pressure (head trauma, cerebral hemorrhage),Acute circulatory failure (shock, vascular collapse)
Avoid alcohol as it may cause hypotension. No specific food interactions; maintain usual diet.
Avoid excessive alcohol consumption. No specific food interactions; however, high-fat meals may delay absorption of oral formulations. Maintain consistent dietary habits to minimize variations in drug effects.
Pregnancy Category C. Animal studies have shown fetal harm (bradycardia, reduced birth weight). Inadequate human data for first trimester; avoid unless benefit outweighs risk. Second and third trimesters: associated with maternal hypotension and fetal bradycardia; use only if clearly needed.
Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. It should be used during pregnancy only if clearly needed. Potential fetal risks include hypotension and reduced uteroplacental perfusion, particularly in the first trimester. Second and third trimester risks are theoretical due to maternal hemodynamic changes. Avoid use near term due to risk of neonatal methemoglobinemia. FDA pregnancy category C.
Excreted in breast milk in small amounts; M/P ratio approximately 0.5. Although risk to infant appears low, caution is advised. Monitor infant for hypotension, methemoglobinemia (rare).
Excretion in human milk is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., methemoglobinemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. M/P ratio not reported.
No formal dose adjustment studies in pregnancy. Pharmacokinetic changes (increased plasma volume, altered protein binding) may require upward titration. Start at lowest effective dose and titrate based on maternal hemodynamic response (BP, HR). Avoid maternal hypotension (systolic <100 mm Hg).
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, no specific dose adjustments are established. Use lowest effective dose with careful titration to avoid hypotension. Initiate with 5-10 mg sublingual for acute episodes; for prophylaxis, 10-40 mg orally every 6 hours. Monitor for excessive hypotension.
NITRO-BID (nitroglycerin ointment) is used for prophylaxis of angina pectoris. Apply to hairless skin, preferably chest or upper arm. Rotate sites to avoid irritation. Do not rub in; spread thin layer. Tolerance develops with continuous use; remove at bedtime to provide nitrate-free interval. Avoid in patients with severe hypotension, hypertrophic obstructive cardiomyopathy, or concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil).
Isordil (isosorbide dinitrate) is a nitrate vasodilator used for angina prophylaxis. Sublingual formulation provides rapid onset for acute attacks; oral sustained-release is for chronic prophylaxis. Tolerance develops with continuous exposure; use a daily nitrate-free interval of 10-12 hours. Avoid use with PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) due to severe hypotension. Monitor for headache, hypotension, and reflex tachycardia.
Apply the prescribed amount to skin, do not rub in.,Wash hands after application.,Rotate application sites to prevent skin irritation.,Remove the ointment at bedtime to prevent tolerance.,Store at room temperature away from heat and open flame.,Seek emergency care if chest pain persists after use.
Take sublingual isordil at the first sign of an angina attack; sit down before using to avoid dizziness.,For chronic prophylaxis, take as prescribed; do not skip doses to maintain the nitrate-free interval.,Avoid alcohol as it can increase the risk of hypotension and dizziness.,Report any severe headaches, worsening chest pain, or fainting to your healthcare provider immediately.,Never take erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on isordil.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRO-BID vs ISORDIL, answered by our medical review team.
NITRO-BID is a Nitrate Vasodilator that works by Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.. ISORDIL is a Nitrate Vasodilator that works by Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing c GMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRO-BID and ISORDIL depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRO-BID is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.. The standard adult dose of ISORDIL is: Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRO-BID and ISORDIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRO-BID is classified as Category C. Pregnancy Category C. Animal studies have shown fetal harm (bradycardia, reduced birth weight). Inadequate human data for first trimester; avoid unless benefit outweighs risk. Seco. ISORDIL is classified as Category C. Isosorbide dinitrate (ISORDIL) is an organic nitrate vasodilator. Animal studies have not demonstrated teratogenic effects, but adequate human studies in pregnant women are lacking. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.